Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerSuzanne L. Topalian, Mario Sznol, F. Stephen Hodi et al.|New England Journal of Medicine|2012Cited by 12.6k
Integrative Clinical Genomics of Advanced Prostate CancerDan R. Robinson, Susana Miranda, Stephen B. Solomon et al.|Cell|2015Cited by 3.6k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L. Topalian, F. Stephen Hodi, Mario Sznol et al.|Journal of Clinical Oncology|2014Cited by 2.2k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerScott Gettinger, Julie R. Brahmer, Leora Horn et al.|Journal of Clinical Oncology|2015Cited by 1.2k
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot StudySameek Roychowdhury, Arul M. Chinnaiyan, Matthew K. Iyer et al.|Science Translational Medicine|2011Cited by 637